CD47 cancer immunotherapy targets a specific “don’t eat me” protein that tumors display to evade detection by the body’s immune system, according to the National Cancer Institute. By blocking this surface signal, researchers aim to help macrophages recognize and destroy malignant cells.
How CD47 Signals Immune Evasion in Tumors
Malignant cells frequently overexpress the CD47 protein on their outer membranes, functioning as a molecular shield. According to research published by the National Institutes of Health, this protein binds to SIRP-alpha receptors on macrophages, transmitting an inhibitory signal that halts phagocytosis. Normal cells express low levels of CD47 to signal self-recognition, but cancer cells exploit this mechanism to prevent immune clearance. Blockade therapies disrupt this interaction, allowing the immune system to target the tumor.
Clinical Development of CD47 Blockade Therapies
Pharmaceutical developers are evaluating multiple monoclonal antibodies and fusion proteins designed to interrupt the CD47-SIRP-alpha axis. According to clinical trial data tracked by the U.S. Food and Drug Administration, these agents are studied primarily in hematologic malignancies and solid tumors, often in combination with opsonizing antibodies that tag cancer cells for destruction. Managing anemia remains a primary clinical focus during trials, as red blood cells also express baseline levels of CD47.
Frequently Asked Questions
What is the primary function of CD47 in the human body?
CD47 acts as a ubiquitous marker of self on healthy cells, communicating with immune cells to prevent the destruction of healthy tissue, according to data from the National Cancer Institute.
Why do cancer cells use CD47?
Tumors upregulate CD47 to deceive macrophages, effectively hiding from immune surveillance and evading phagocytosis.
What are the main challenges in developing CD47-targeted drugs?
Because normal red blood cells and platelets express CD47, therapies must avoid causing unintended clearance of healthy blood cells, a challenge documented in clinical evaluations by oncology researchers.
Related reading